Cargando…
Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
BACKGROUND: Lenvatinib inhibits tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor alpha, RET proto-oncogene and KIT proto-oncogene, receptor tyrosine kinase. We assessed the efficacy and safety o...
Autores principales: | Iwasa, Satoru, Okita, Natsuko, Kuchiba, Aya, Ogawa, Gakuto, Kawasaki, Mamiko, Nakamura, Kenichi, Shoji, Hirokazu, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Boku, Narikazu, Yamada, Yasuhide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440718/ https://www.ncbi.nlm.nih.gov/pubmed/32817132 http://dx.doi.org/10.1136/esmoopen-2020-000776 |
Ejemplares similares
-
Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
por: Watanabe, Sho, et al.
Publicado: (2017) -
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022) -
Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
por: Tada, Kohei, et al.
Publicado: (2015) -
Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020) -
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)